We have located links that may give you full text access.
Journal Article
Review
Prevalence and Thrombotic Risk Assessment of Anti-β2 Glycoprotein I Domain I Antibodies: A Systematic Review.
Seminars in Thrombosis and Hemostasis 2018 July
BACKGROUND: To date, the exact prevalence of anti-β2 glycoprotein I domain I (anti-β2 GPI-DI) antibodies in patients with antiphospholipid syndrome (APS) and their role when assessing thrombosis risk is uncertain.
OBJECTIVES: To estimate the prevalence of anti-β2 GPI-DI in patients with APS and to determine whether anti-β2 GPI-DI-positive individuals are at greater risk of thrombosis, as compared with individuals without anti-β2 GPI-DI, by systematically reviewing the literature.
METHODS: A detailed literature search was applied a priori to Ovid MEDLINE In-Process and Other Non-Indexed Citation 1986 to present and to abstracts from the European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR)/Association for Rheumatology Health Professionals (ARHP ) Annual Meetings (2011-2015).
RESULTS: A total of 11 studies, including 1,585 patients, were analyzed. Patients were distributed as follow: 1,218 patients APS (45.4% anti-β2 GPI-DI-positive; in more detail: 504 primary APS [55.4% anti-β2 GPI-DI-positive], 192 secondary APS [43.2% anti-β2 GPI-DI-positive], and 522 not specified), 318 with systemic lupus erythematosus (SLE; 26.7% anti-β2 GPI-DI-positive), 49 asymptomatic carriers of antiphospholipid antibodies (aPL) (30.6% anti-β2 GPI-DI-positive), and 1,859 healthy controls. When considering the five studies eligible for thrombotic risk assessment, four studies found a significant association of anti-β2 GPI-DI-positivity with thrombotic events, whereas one study found no predictive correlation with thrombosis (overall odds ratio [OR] for pooled data: 1.99; 95% confidence interval [CI]: 1.52-2.6; p < 0.0001).
CONCLUSION: We report an overall estimated median prevalence of anti-β2 GPI-DI antibodies of 44.3% in patients with APS and/or SLE and a significantly higher prevalence among patients with APS compared with SLE alone. Anti-β2 GPI-DI antibodies might represent a promising tool when assessing thrombotic risk in patients with APS.
OBJECTIVES: To estimate the prevalence of anti-β2 GPI-DI in patients with APS and to determine whether anti-β2 GPI-DI-positive individuals are at greater risk of thrombosis, as compared with individuals without anti-β2 GPI-DI, by systematically reviewing the literature.
METHODS: A detailed literature search was applied a priori to Ovid MEDLINE In-Process and Other Non-Indexed Citation 1986 to present and to abstracts from the European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR)/Association for Rheumatology Health Professionals (ARHP ) Annual Meetings (2011-2015).
RESULTS: A total of 11 studies, including 1,585 patients, were analyzed. Patients were distributed as follow: 1,218 patients APS (45.4% anti-β2 GPI-DI-positive; in more detail: 504 primary APS [55.4% anti-β2 GPI-DI-positive], 192 secondary APS [43.2% anti-β2 GPI-DI-positive], and 522 not specified), 318 with systemic lupus erythematosus (SLE; 26.7% anti-β2 GPI-DI-positive), 49 asymptomatic carriers of antiphospholipid antibodies (aPL) (30.6% anti-β2 GPI-DI-positive), and 1,859 healthy controls. When considering the five studies eligible for thrombotic risk assessment, four studies found a significant association of anti-β2 GPI-DI-positivity with thrombotic events, whereas one study found no predictive correlation with thrombosis (overall odds ratio [OR] for pooled data: 1.99; 95% confidence interval [CI]: 1.52-2.6; p < 0.0001).
CONCLUSION: We report an overall estimated median prevalence of anti-β2 GPI-DI antibodies of 44.3% in patients with APS and/or SLE and a significantly higher prevalence among patients with APS compared with SLE alone. Anti-β2 GPI-DI antibodies might represent a promising tool when assessing thrombotic risk in patients with APS.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app